sábado, outubro 21, 2006

Competição para Norvir?

Merck buys protease inhibitor from Ambrilia, may be potent booster of other PIs

Aidsmap 20.10.06

Merck & Co announced last week that it has licensed an experimental protease inhibitor that does not require ritonavir boosting and which may be active against highly drug-resistant HIV. The compound, PPL-100, was developed by Ambrilia Biopharma (formerly Procyon) and previously by Pharmacor, both Montreal-based companies. PPL-100 appears to be just as potent a booster of other HIV protease inhibitors as ritonavir (Norvir).

Comments: Enviar um comentário

<< Home

This page is powered by Blogger. Isn't yours?

Enter your email address below to subscribe to Blog do GAT!

powered by Bloglet